Segmental Reporting (Tables)

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Schedule of Segment Revenue from Major Products

	3 Months Ended March 31,
	2016	2015
	$’M	$’M
	___________	___________
VYVANSE	509.2	416.8
LIALDA/MEZAVANT	168.0	148.5
CINRYZE	164.2	148.1
FIRAZYR	128.3	92.5
ELAPRASE	123.6	125.0
REPLAGAL	103.2	97.5
ADDERALL XR	98.8	95.7
VPRIV	83.6	86.4
PENTASA	64.0	78.7
GATTEX/REVESTIVE	51.7	14.9
FOSRENOL	37.7	44.1
XAGRID	28.3	25.3
NATPARA	15.6	-
KALBITOR	10.4	-
INTUNIV	10.2	17.4
Other product sales	30.5	32.3
	____________	____________
Total product sales	1,627.3	1,423.2
	____________	____________